KRAS mutation-related tumors
Clinical trials for KRAS mutation-related tumors explained in plain language.
Never miss a new study
Get alerted when new KRAS mutation-related tumors trials appear
Sign up with your email to follow new studies for KRAS mutation-related tumors, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
Disease control Recruiting nowThis trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase 1/2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests the safety of combining an experimental drug called NEROFE with a standard chemotherapy, doxorubicin, in people with advanced solid tumors that have a KRAS mutation and express ST2. The trial aims to find the best dose and schedule for the combination…
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase 1 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC